2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1304

2D and 3D Measurements of Osteoarthritis Joint Space Width Have Good Agreement in Radiographically Normal Knees but Poor Agreement with Advancing Kellgren-Lawrence Grade: Data from the Osteoarthritis Initiative
Abstract Number: 1557

3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-like T Cells in Rheumatoid Arthritis
Abstract Number: 768

7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 164

99mtc-Hdp Digital Blood Flow Scintigraphy for Assessment of Raynaud Phenomenon Associated with Hand-Arm Vibration Syndrome
Abstract Number: 909

A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Abstract Number: 1651

A Case Series on Patients on Tofacitinib in Combination with a Biologic
Abstract Number: 2018

A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma
Abstract Number: 1212

A Combined Large Scale Meta-Analysis Identifies COG6 As a Novel Shared Risk Locus for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 2973

A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Abstract Number: 332

A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis
Abstract Number: 2911

A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
Abstract Number: 2601

A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Abstract Number: 2014

A Deep Insight into Causes and Predictors of Death in Systemic Sclerosis
Abstract Number: 2240

A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Abstract Number: 1233

A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].